Real-time regulatory updates from DEA, DOJ, FDA, CMS, and all 50 state medical boards — curated and analyzed by AI, reviewed by compliance experts. Built to help you stay ahead of healthcare regulation changes.
All 50 States + DC
350+ Regulatory Topics
Regulatory Intelligence Feed
0 articles published
Guides & Templates
In-Depth Compliance Resources
Comprehensive guides, checklists, and templates to help you navigate healthcare compliance — from CPOM structuring to GFE requirements and medical director agreements.
Our AI-powered intelligence engine monitors DEA, DOJ, FDA, CMS, and all 50 state medical boards so you never miss a compliance update that affects your business.
The Federal Trade Commission (FTC) has approved a final order against TruHeight (Vanilla Chip LLC) for making deceptive claims regarding children's supplements. This enforcement action resulted in a $4 million judgment, of which $750,000 will be paid by the company.
The Department of Justice (DOJ) announced its 2026 National Health Care Fraud Takedown on June 23, 2026, charging 455 defendants in an alleged $6.5 billion fraud. A substantial $1.2 billion portion of this alleged fraud specifically targeted telemedicine schemes, with the alleged mastermind of this segment arrested in the Philippines.
A Brooklyn adult daycare owner has been sentenced to 57 months in prison for leading a $3.2 million Medicaid fraud and illegal kickback scheme. The defendant paid cash bribes to Medicaid recipients for enrollment in Prime Life Adult Day Care LLC, then billed Medicaid for services never provided. In addition to prison time, he was ordered to pay nearly $3.2 million in restitution and forfeit $1.5 million in fraud proceeds.
The Drug Enforcement Administration (DEA) has published a correcting amendment to formally update the chemical name for bromazolam, a substance temporarily placed in Schedule I of the Controlled Substances Act on March 16, 2026. This correction ensures accurate identification of bromazolam, which remains classified as a Schedule I substance due to its high potential for abuse and no accepted medical use.
The FDA is proposing new regulations for the format, content, and procedures for establishment registration and tobacco product listing. This proposed rule aims to address current information gaps by extending these registration and listing requirements to include owners and operators of foreign establishments, which are currently exempt.
The FDA has issued a final rule classifying the monitor for opioid induced impairment of oxygenation into Class II with special controls. This action aims to provide reasonable assurance of the device's safety and effectiveness while reducing regulatory burdens and enhancing patient access to beneficial innovative devices.
The Drug Enforcement Administration (DEA) has issued a notice of intent to temporarily place three 7-hydroxymitragynine-related substances—mitragynine pseudoindoxyl, MGM-15, and MGM-16—into Schedule I of the Controlled Substances Act (CSA). This action is taken under emergency scheduling provisions, aiming to impose stringent regulatory controls due to an imminent hazard to public safety.
The Drug Enforcement Administration (DEA) is proposing to classify phenethyl halides as List I chemicals under the Controlled Substances Act (CSA). These chemicals are critical precursors in the illicit production of fentanyl and its analogues. If finalized, this rule would require all handlers of phenethyl halides, regardless of transaction size, to comply with stringent CSA chemical regulations.
The National Cancer Institute (NCI), an agency of the Department of Health and Human Services (HHS), is actively seeking research co-development partners and/or licensees. This opportunity focuses on viral peptide (CE1)-based therapeutics designed for the prevention and treatment of hepatocellular carcinoma (HCC), a prevalent and aggressive form of liver cancer. This initiative aims to advance novel immunotherapies, such as a CE1-based HCC vaccine, given the current limitations in HCC treatment options.
The Department of Health and Human Services (HHS) is requesting public comments on a proposed threshold for 7-hydroxymitragynine (7-OH), a substance the DEA intends to temporarily place in Schedule I of the Controlled Substances Act (CSA). This request for information focuses specifically on data supporting the defined concentration levels that would constitute an 'imminent hazard to public safety.' The public comment period closes on July 31, 2026.
The FDA has approved crucial updates to the 'Drugs Facts Label' for the over-the-counter (OTC) weight loss medication, alli (orlistat) 60 mg capsules, to include warnings about rare but serious risks of acute kidney injury, kidney stones, and other kidney-related issues. The revised labeling advises consumers to consult a healthcare provider if they have a history of kidney disease or stones and to cease use and seek medical attention if symptoms of kidney injury develop. These warnings are now consistent across all FDA-approved orlistat products, including the higher-strength prescription version, Xenical.
The U.S. Food and Drug Administration (FDA) has approved Rextovy, a 4 mg naloxone hydrochloride nasal spray, for over-the-counter (OTC) sale, allowing direct consumer purchase without a prescription. This action broadens access to a life-saving medication for emergency opioid overdose treatment, aligning with federal efforts to combat the addiction crisis. It provides an additional readily available option for individuals to reverse opioid overdose effects and aims to reduce overdose deaths.
The Centers for Medicare & Medicaid Services (CMS) has issued a Request for Information (RFI) to gather technical input on the services and business practices of Pharmacy Benefit Managers (PBMs) and their affiliates. This RFI aims to inform the implementation of recent legislation concerning PBM remuneration restrictions and data reporting requirements, both set to become effective in Calendar Year 2028.
The Food and Drug Administration (FDA) has issued a final order debarring Andrew Jonathan Morgan for a period of 5 years from importing or offering for import any drug into the United States. This action stems from Mr. Morgan's felony conviction under federal law for conduct relating to the importation of a drug or controlled substance. Mr. Morgan waived his right to a hearing by not responding to the proposed debarment notice.
A former U.S. Intelligence Community contractor, David Duggin, has pleaded guilty to conspiring to commit offenses against the United States by soliciting and accepting over $510,000 in illegal kickbacks. This federal case underscores the Department of Justice's robust enforcement efforts against individuals who corrupt government procurement processes for personal gain. The DOJ's Procurement Collusion Strike Force (PCSF) continues to target fraudulent schemes impacting government funding at all levels.
